Transparent timing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Industry should have a better idea by the end of February regarding just how far FDA might go in releasing information in "complete response" letters, withdrawn applications and other material associated with drug applications that currently is withheld from the public, FDA Principal Deputy Commissioner Joshua Sharfstein indicated Jan. 12. Sharfstein was unveiling the first part of FDA's transparency initiative, a public Web site with basic information, but he reported the second phase, "about what information does FDA have in its possession and now is not accessible, what information will we make accessible," will follow shortly. A third phase of the transparency initiative will address industry desires to obtain clarification about ambiguous rules and more information on the basis for agency decisions (1"The Pink Sheet" DAILY, Nov. 13, 2009). The transparency task force, headed by Sharfstein, will recommend to Commissioner Margaret Hamburg which information can be released while still protecting confidentiality. The recommendations will be made available for public comment before Hamburg decides on a final plan of action
You may also be interested in...
FDA Is Expanding Transparency Efforts To Focus On Industry Questions
Sharfstein said the agency has split up its transparency efforts into three groups, adding one dedicated to explaining its inner workings to regulated industry.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.